

To
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, MUMBAI – 400 001.

Date: 31-01-2023

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on 31-01-2023

Unit: Hindustan Bio Sciences Limited (Scrip Code: 532041)

With reference to the subject cited, this is to inform the exchange that at the Board Meeting of Hindustan Bio Sciences Limited held on Tuesday, the 31st day of January, 2023 at 02.00 p.m. at the registered office of the company at Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad-500034, Telangana, the following were considered and approved:



1. Un-audited financial results of the company for the quarter ended 31st December, 2022 (enclosed as annexure)
2. Limited Review Report for the quarter ended 31st December, 2022. (enclosed as annexure)
3. The Resignation submitted by Mr. Varuna Varma Jampana Director of the Company is accepted.

The meeting concluded at 3.00 PM

Thanking you

Yours faithfully,

For **Hindustan Bio Sciences Limited**



VENKATA RAMA MOHAN RAJU JAMPANA
Managing Director
(DIN: 00060800)

HINDUSTAN BIO SCIENCES LIMITED
Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034
Phone No. 23555161, Fax 40205171

STATEMENT OF UN AUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2022


(Rs. In lakhs)

Sl. No.	Particulars	Quarter ended			Nine Months Ended		Year ended
		31.12.2022 (Unaudited)	30.09.2022 (Unaudited)	31.12.2021 (Unaudited)	31.12.2022 (Unaudited)	31.12.2021 (Unaudited)	31.03.2022 (Audited)
1	Income from Operations						
	(a) Revenue from operations	31.81	-	23.96	58.95	43.38	43.06
	(b) Other Income	-	-	-	-	5.24	-
	Total Revenue (1)	31.81	-	23.96	58.95	48.62	43.06
2	Expenses						
	(a) cost of material consumed	-	-	-	-	-	-
	(b) Purchases of Stock -in-trade	18.29	-	15.90	36.58	28.93	23.69
	(c) Changes in inventories of finished goods, Stock - in-Trade and Work-in-Progress	-	-	-	-	-	-
	(d) Employee Benefit Expenses	5.96	6.12	5.93	18.01	18.11	24.05
	(e) Finance Costs	0.11	0.06	0.13	0.20	0.28	0.60
	(f) Selling Expenses	0.57	-	0.38	0.90	0.61	0.61
	(g) Depreciation and amortisation Expenses	0.11	0.11	0.08	0.32	0.24	0.34
	(h) Other Expenses	2.01	1.20	1.74	8.18	13.72	45.32
	Total Expenses(2)	27.05	7.49	24.16	64.19	61.89	94.51
3	Profit/(Loss) before Exceptional& Extraordinary items and tax (1 -2)	4.76	(7.49)	(0.20)	(5.24)	(13.27)	(51.45)
4	Exceptional items	-	-	-	-	-	-
5	Profit/(Loss) before tax(3 -4)	4.76	(7.49)	(0.20)	(5.24)	(13.27)	(51.45)
6	Tax Expenses						
	(a) Current Tax	-	-	-	-	-	-
	(b) previous Taxes	-	-	-	-	0.03	0.03
	(b) Deferred Tax	-	-	-	-	-	0.34
7	Profit /(Loss) for the period from continuing operations(5-6)	4.76	(7.49)	(0.20)	(5.24)	(13.24)	(51.76)
8	Profit /(Loss) from discontinued operations	-	-	-	-	-	-
9	Tax Expense of discontinued operations	-	-	-	-	-	-
10	Profit /Loss from Discontinued operations after tax(8-9)	-	-	-	-	-	-
11	Profit/(Loss) for the period(7+10)	4.76	(7.49)	(0.20)	(5.24)	(13.24)	(51.76)
12	Other Comprehensive Income						
	A (1) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(2) Income tax relating to items that will not be re- classified to profit or loss	-	-	-	-	-	-
	B (1) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(2) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period (11+12) (comprising Profit (Loss) and other comprehensive income for the period	4.76	(7.49)	(0.20)	(5.24)	(13.24)	(51.76)
14	Paid up Equity Capital(Face value of Rs. 10/- each)	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						(946.37)
16	Earnings per equity share for continuing operations						
	(A) Basic	0.05	(0.07)	(0.00)	(0.05)	(0.13)	(0.50)
	(B) Diluted	0.05	(0.07)	(0.00)	(0.05)	(0.13)	(0.50)
17	Earnings per equity share for discontinuing operations						
	(A) Basic	-	-	-	-	-	-
	(B) Diluted	-	-	-	-	-	-
18	Earnings per equity share(for discontinuing & continuing operations						
	(A) Basic	0.05	(0.07)	(0.00)	(0.05)	(0.13)	(0.50)
	(B) Diluted	0.05	(0.07)	(0.00)	(0.05)	(0.13)	(0.50)

Notes:


- The Un Audited Financial Results were taken on record by the Board of Directors in their meeting held on 31.01.2023
- Previous Year figures have been regrouped wherever necessary.

Place: Hyderabad
Date: 31.01.2023



for Hindustan Bio Sciences Limited

VENKATA RAMA MOHAN RAJU JAMPANA
Managing Director
(DIN:00060800)



VASG & ASSOCIATES
Chartered Accountants

503/A, 5th Floor, Kubera Towers,
Narayanaguda, Hyderabad - 500 029.
Ph : 040-66849660 / 66887732
E-mail : info@vasg-ca.com
vasgassociates@gmail.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
M/S HINDUSTAN BIO SCIENCES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of M/S. **HINDUSTAN BIOSCIENCES LIMITED** (the "Company"), for the quarter and period ended December 31, 2022, being prepared by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended.

The preparation of this statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('IND AS 34'), prescribed under section 133 of the companies act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India is the responsibility of the company's management and has been approved by the Board of Directors of the company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit, we have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VASG & ASSOCIATES
Chartered Accountants
FRN: 006070S



(Signature)
(A. Viswanatha Rao)
Partner
M.No: 029597
UDIN: 23029597BGTFNU8619
Date: 31/01/2023